Menu

Federal Contractor Misconduct Database (FCMD)

The federal government routinely awards contracts to companies with histories of misconduct, including contract fraud and other violations. POGO believes that providing this website will help to improve contracting decisions and increase public knowledge of how the government spends billions of taxpayer dollars each year. Read more…

Controlled Substances Act Violations in Florida, Maryland, New York and Washington State

Cardinal Health agreed to pay $34 million in civil penalties to resolve allegations that it failed to report to the U.S. Drug Enforcement Administration (DEA) suspicious orders of Class II controlled substances (including oxycodone) by pharmacies located in Florida and Maryland from January 2009 to May 2012. The settlement also resolved a federal civil investigation into Cardinal Health’s failure to maintain adequate records concerning controlled substances in Washington State. Separately, Kinray LLC, a pharmaceutical distributor owned by Cardinal Health, agreed to pay $10 million to resolve allegations that it failed to report suspicious orders of oxycodone or hydrocodone by New York-area pharmacies between January 2011 and May 2012. As part of the settlement, Kinray accepted responsibility for failing to inform the DEA.

Misconduct Type
Health
Enforcement Agency
Justice
Contracting Party
None
Court Type
Civil
Disposition
Settlement
Date of Settlement Announcement
12/23/2016
Contractors Involved Penalty
Total
Cardinal Health, Inc. $44,000,000
Further Information Released
Cardinal Health Press Release 12/23/2016
DEA Press Release (New York) 12/23/2016
DOJ Press Release (Florida) 12/23/2016
DOJ Press Release (Maryland) 12/23/2016

Federal Contractor Misconduct Database